Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialHertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al.|The Lancet|2019Cited by 3kOpen Access
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trialHertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al.|The Lancet|2019Cited by 622Open Access